Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

Qichen Zhanga University of Lanzhou of the First School of Clinical Medicine, Lanzhou, ChinaView further author information

Peng Xieb Department of Radiation Oncology, The First Hospital of Lanzhou University, Lanzhou, ChinaView further author information

Xiaoming Houc Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, ChinaView further author information

Chengpeng Zhaoc Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, ChinaView further author information

Ling Duanc Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, ChinaView further author information

Hui Qiaoc Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China;d School of Life Sciences, Lanzhou University, Lanzhou, ChinaCorrespondence[email protected]

https://orcid.org/0000-0003-2347-4826 View further author information

Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date